These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28031240)

  • 1. Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
    Miyata H; Ashizawa T; Iizuka A; Kondou R; Nonomura C; Sugino T; Urakami K; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K; Akiyama Y
    Cancer Genomics Proteomics; 2017 Jan; 14(1):83-91. PubMed ID: 28031240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
    Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
    Akiyama Y; Nonomura C; Ashizawa T; Iizuka A; Kondou R; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Asai A; Ito M; Kiyohara Y; Yamaguchi K
    Immunol Lett; 2017 Oct; 190():20-25. PubMed ID: 28716484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
    Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
    Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
    Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
    Zhou RJ; Xu XY; Liu BX; Dai WZ; Cai MQ; Bai CF; Zhang XF; Wang LM; Lin L; Jia SZ; Wang WH
    Int J Mol Med; 2015 Oct; 36(4):1159-64. PubMed ID: 26310668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
    Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
    Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
    Han TJ; Cho BJ; Choi EJ; Kim DH; Song SH; Paek SH; Kim IA
    J Neurooncol; 2016 Oct; 130(1):89-98. PubMed ID: 27510952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
    Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
    Wang Y; Chen L; Bao Z; Li S; You G; Yan W; Shi Z; Liu Y; Yang P; Zhang W; Han L; Kang C; Jiang T
    Oncol Rep; 2011 Nov; 26(5):1173-80. PubMed ID: 21887474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
    Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
    Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
    Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
    Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
    Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
    Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.